This site is intended for U.S. Healthcare Professionals.

Visit EUA Option for 6 Months - 11 Years of Age
Visit Approved Vaccine Option for 12+ Years of Age
Indication
Prescribing
Information (English)
Prescribing
Information (Spanish)
Patient
Information
(English)
Patient
Information
(Spanish)

Emergency Use Authorization (EUA)1

Emergency uses of COVID-19 vaccines from BioNTech and Pfizer, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 6 months of age and older. Emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical products under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com.

Emergency Use Authorization (EUA)

AUTHORIZED: Effective 08/22/24

PFIZER-BIONTECH COVID-19 VACCINE (2024-2025 FORMULA) IS AUTHORIZED FOR EMERGENCY USE FOR ACTIVE IMMUNIZATION TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) IN INDIVIDUALS 6 MONTHS THROUGH 11 YEARS OF AGE.

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)

Click to view the EUA Fact Sheet for Vaccination Providers.

To prevent vaccine administration errors, prior to preparation and administration:

  • Please verify that vial labels state “Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)”
  • Verify the cap color and label are for the respective authorized age group

Please see the Vaccine Presentation & Dosing Guide for more details.

Important Reminder:

Previous COVID-19 vaccines are no longer available for use in the United States.

FDA and CDC guidance is to check inventory and dispose of previous COVID-19 vaccines according to state and local regulations.

Regardless of storage condition, the vaccine should not be used after the expiration date printed on the vials and cartons.

Read the Important Safety Information below and check back for further updates.

Select Important Vial Information

To Prevent Vaccine Administration Errors, Prior to Preparation for Administration:

Please verify that vial labels state "Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula).”

Verify the vial cap color and label for the respective authorized age group.

Vaccine Presentation & Dosing Guide

Refer to the information outlined below for select information about the vaccine and presentations.

Vaccine Presentation & Dosing Guide

For Eligible Individuals 6 Months Through 4 Years of Age

Expand All

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)
6 MONTHS THROUGH 4 YEARS* OF AGE, DILUTE BEFORE USE

Yellow Cap1

Dosing Information

Dose

3 mcg†

Dose volume

0.3 mL†

Dilution‡

1.1 mL‡

Doses per vial

Multiple-Dose Vial:
3 doses per vial (after dilution)§

For eligibility, dosing schedule, and other important information, please see EUA Fact Sheet.

Storage Conditionsll

Ultra-low-temperature (ULT) freezer
[-90°C to -60°C (-130°F to -76°F)]

18 months

Freezer
[-25°C to -15°C (-13°F to 5°F)]

DO NOT STORE

Refrigerator
[2°C to 8°C (35°F to 46°F)]

10 weeks

Room temperature
[8°C to 25°C (46°F to 77°F)]

12 hours prior to first puncture

After first puncture
[2°C to 25°C (35°F to 77°F)]

Discard 12 hours after the first puncture#

* For individuals turning from 4 to 5 years of age during the vaccination series who have received 1 or 2 doses of Pfizer-BioNTech COVID-19 Vaccine, administer a single dose of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) supplied in vials with blue caps and labels with blue borders, on or after the date the individual turns 5 years of age.

† After dilution, each 0.3 mL dose is formulated to contain 3 mcg of modRNA encoding Omicron variant lineage KP.2.

‡ ONLY use sterile 0.9% Sodium Chloride Injection, USP, as the diluent.

§ If the amount of vaccine in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. Do not pool excess vaccine from multiple vials.

|| During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Do not refreeze thawed vials.

# After dilution, multiple dose vials should be held between 2°C to 25°C (35°F to 77°F). Multiple dose vials should be discarded 12 hours after dilution.

For Eligible Individuals 5 Through 11 Years of Age

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)
5 THROUGH 11 YEARS* OF AGE, DO NOT DILUTE

Blue Cap1

Dosing Information

Dose

10 mcg†

Dose volume

0.3 mL†

Dilution

DO NOT DILUTE

Doses per vial

Single Dose Vial:
1 dose per vial

For eligibility, dosing schedule, and other important information, please see EUA Fact Sheet.

Storage Conditions‡

Ultra-low-temperature (ULT) freezer§
[-90°C to -60°C (-130°F to -76°F)]

18 months

Freezer
[-25°C to -15°C (-13°F to 5°F)]

DO NOT STORE

Refrigerator
[2°C to 8°C (35°F to 46°F)]

10 weeks

Room temperature
[8°C to 25°C (46°F to 77°F)]

12 hours prior to use

* For individuals turning from 4 to 5 years of age during the vaccination series who have received 1 or 2 doses of Pfizer-BioNTech COVID-19 Vaccine, administer a single dose of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) supplied in vials with blue caps and labels with blue borders, on or after the date the individual turns 5 years of age.

† Each 0.3 mL dose is formulated to contain 10 mcg of modRNA encoding Omicron variant lineage KP.2.

‡ During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

§ Do not refreeze thawed vials.

Shipping & Handling Resources

Return Instructions for Shipping Containers Dry Ice Safety Data Sheet Single-Use Shipping Container Shipping & Handling Guidelines Medium Thermal Shipping Container Shipping & Handling Guidelines Product Safety Data Sheet
Reference
1.

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (6 months through 11 years of age); BioNTech Manufacturing GmbH and Pfizer Inc.; August 22, 2024.

Ordering Available Through Pfizer Prime*

Orders for 2024-2025 formula COVID-19 vaccines by BioNTech and Pfizer can be placed by eligible healthcare professionals directly with Pfizer through Pfizer Prime online or by calling 1-800-533-4535.

*Eligible healthcare providers can order COVID-19 vaccines directly from Pfizer. If preferred, orders may be placed with your facility’s wholesaler.

IMPORTANT SAFETY
INFORMATION

 

AUTHORIZED USE

Indication & Authorized Use

IMPORTANT SAFETY INFORMATION

Expand

Collapse

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.

Important Safety Information

Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of Pfizer-BioNTech COVID-19 Vaccine.

Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention (CDC) guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis

Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations
/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to Pfizer-BioNTech COVID-19 Vaccine.

Limitation of Vaccine Effectiveness

Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Adverse Reactions

Solicited adverse reactions included:

  • 6 months through 23 months of age: Injection site redness; swelling and tenderness; decreased appetite; drowsiness; fever; irritability.
  • 2 through 11 years of age: Injection site pain; redness and swelling; chills; diarrhea; fatigue; fever; headache; new or worsened joint pain; new or worsened muscle pain; vomiting.

Vaccination providers must report all vaccine administration errors, all serious adverse events, cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS), and cases of COVID-19 that result in hospitalization or death following administration of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) to the Vaccine Adverse Event Reporting System (VAERS) by submitting online at https://vaers.hhs.gov/reportevent.html. Vaccination providers administering COMIRNATY (COVID-19 Vaccine, mRNA) (2024-2025 Formula) under EUA must adhere to the same reporting requirements. For further assistance with reporting to VAERS call 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) EUA” in the description section of the report. To the extent feasible, report adverse events to Pfizer 1-800-438-1985 or provide a copy of the VAERS form to Pfizer https://www.pfizersafetyreporting.com/

Please click for Pfizer-BioNTech COVID-19 Vaccine Vaccination Provider and Recipient and Caregiver EUA Fact Sheets.

AUTHORIZED USE

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.

For More Information

Customer Service Icon

Pfizer Customer Service

Call 1-800-879-3477

Medical Information Icon

Medical Information

Visit PfizerMedicalInformation.com

Shipment Icon

Shipment Support
US Trade Customer Service

Call 1-800-666-7248

Vial Icon

General Product Questions

Call 1-800-879-3477

Chat Bubble Icon

Get COVID-19 Vaccine–Related Info Texted Directly to Your Mobile Device

Enroll in the BioNTech & Pfizer COVID Connect text messaging program for U.S. Healthcare Professionals.

Get Started
Phone Representative Icon

Call a Pfizer Connect Representative

Our representatives are available 9 AM - 5 PM ET to provide live support to help healthcare providers answer product questions, explain Pfizer Prime ordering, and more.

Call 1-844-966-5127